EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Iovance Biotherapeutics's enterprise value is $3,083.44 Mil.
Iovance Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-427.43 Mil. Therefore, Iovance Biotherapeutics's EV-to-EBITDA for today is -7.21.
The historical rank and industry rank for Iovance Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
IOVA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.59 Med: -3.72 Max: -1.29
Current: -7.21
During the past 13 years, the highest EV-to-EBITDA of Iovance Biotherapeutics was -1.29. The lowest was -9.59. And the median was -3.72.
IOVA's EV-to-EBITDA is ranked worse than 100% of 473
companies
in the Biotechnology industry
Industry Median: 9.22
vs IOVA: -7.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), Iovance Biotherapeutics's stock price is $11.55.
Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.880. Therefore, Iovance Biotherapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Iovance Biotherapeutics EV-to-EBITDA Historical Data
The historical data trend for Iovance Biotherapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Iovance Biotherapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Iovance Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's EV-to-EBITDA falls into.
Iovance Biotherapeutics EV-to-EBITDA Calculation
Iovance Biotherapeutics's EV-to-EBITDA for today is calculated as:
Iovance Biotherapeutics's current Enterprise Value is $3,083.44 Mil.
Iovance Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-427.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Iovance Biotherapeutics's PE Ratio for today is calculated as:
Iovance Biotherapeutics's share price for today is $11.55.
Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Iovance Biotherapeutics EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Iovance Biotherapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IOVA has been successfully added to your 